RE: Goosed4 Jan 2019 11:29
it was in RNS Sept 2018 .... the change occurred in the wording
The Company subsequently announced the appointment of The PolyPeptide Group, one of the world's largest independent contract manufacturers of therapeutic peptides, for Good Manufacture Practice (GMP)-compliant manufacture of the Modi-1/AMPLIVANT® conjugates with the aim of filing a clinical trial application (CTA) in the UK and commencement of the planned Phase 1/2 clinical trial during 2019.